Catalog No.
DHG93101
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG2-kappa
Clonality
Monoclonal
Target
NMB, Hematopoietic growth factor inducible neurokinin-1 type, HGFIN, GPNMB, Transmembrane glycoprotein NMB
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q14956
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CDX-011 (DOX), CR011, glembatumumab vedotin (ADC), CAS: 1020264-78-1
Clone ID
Glembatumumab
Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer, PMID: 28546082
A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma, PMID: 32823698
The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer, PMID: 22229970
Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE), PMID: 24496926
Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer, PMID: 20373269
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma, PMID: 30690710
Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program, PMID: 24912408
Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma, PMID: 26305408
Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group, PMID: 31586757
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer, PMID: 25847941
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma, PMID: 25267741
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study, PMID: 34016993
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer, PMID: 25267761
Novel Targeted Therapies for Metastatic Melanoma, PMID: 28114255
Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives, PMID: 31272342
Emerging targeted therapies for melanoma, PMID: 27148822
Antibody-drug conjugates in triple negative breast cancer, PMID: 30175620
Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives, PMID: 29439419
Antibodies to watch in 2017, PMID: 27960628
Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent, PMID: 29262642
Antibodies to watch in 2018, PMID: 29300693
Gpnmb/osteoactivin, an attractive target in cancer immunotherapy, PMID: 22017590
Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer, PMID: 23874106
Antibody-drug conjugate for advanced melanoma?, PMID: 25602109
Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer, PMID: 20215530
GPNMB expression in uveal melanoma: a potential for targeted therapy, PMID: 20375921
New developments in metastatic breast cancer: integrating recent data into clinical practice, PMID: 24892840
Novel data in metastatic breast cancer, PMID: 24637556
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB, PMID: 27515299
For research use only. Not for human or drug use.
